$3SBIO(01530.HK) This recent wave has been moving a bit sluggishly. -0.47% isn't a lot, but it's not nothing either. However, this kind of slow, steady decline is even more of a headache... The pharmaceutical sector was thought to have exhausted its negative news and could recover, but it's still dragging its feet like this.
Overview
3SBIO (1530)
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of...
- Open
- 13.700
- High
- 14.440
- Low
- 13.520
- Prev. Close
- 14.440
- Volume
- 19.29M
- Turnover
- 269.60M
- Avg Price
- 13.973
- Bid/Ask Ratio
- -97.46%
- Amplitude
- 6.37%
- 52wk High
- 35.170
- Volume Ratio
- 0.48
- Turnover Ratio
- 0.77%
- 52wk Low
- 13.050
- HK Mkt Cap
- 35.42B
- Market CapHKD
- 35.42B
- P/ETTM
- 3.72
- P/EDynamic
- 13.42
- P/EStatic
- --
- EPSTTM
- 3.79
- EPSDynamic
- 1.05
- EPSStatic
- --
- BVPS
- 12.60
- P/B
- 1.12
- HK Shares
- 2.51B
- Dividend YieldTTM
- 1.79%
- DividendTTM
- 0.252
- Shares
- 2.51B
- Min lot size
- 500
- Currency
- HKD
3SBIO Analyst Rating
View moreForecast & Rating
Nov 11, 2026- Strong buy64.29%
- Buy28.57%
- Hold7.14%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 9
- Buy
- 4
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
3SBio opened 5.1% lower but clawed back to close at HK$14.19, down 1.73%, after touching HK$13.56 at 09:31 BJ and rebounding to HK$14.26 at 13:04 BJ on HK$258 million turnover; a fresh 5% slide during Hong Kong hours and proposed US curbs on Chinese biotech investment kept sentiment on the sector subdued. Fundamentals cut against the tape: Q2 2026 revenue rose 9.54% year on year to HK$2.61 billion and operating profit gained 29.88% to HK$891 million, yet net profit fell 11.01% to HK$662 million and EPS slipped 16.56% to HK$0.256. The shares trade below the MA20 of HK$14.32 and MA60 of HK$15.47, down 42.27% year to date, 59.94% below the 52-week high of HK$35.42 and only 8.74% above the HK$13.05 low, on a 3.75x PE. UBS and Citic Securities have nonetheless kept Buy ratings.
- Nov, 5
3SBio rose 4.41% to HK$15.40 from HK$14.75, staging a high-open rebound after an early dip as UBS reaffirmed its rating and Guosheng Securities highlighted China's improving pharmaceutical innovation efficiency, lifting sentiment across Hong Kong innovative-drug names. The stock opened at HK$15.00, dipped to HK$14.80, reached HK$15.56 at 09:52 in the morning session, then consolidated between HK$15.13 and HK$15.50 in the afternoon on HK$391m turnover. Q2 2026 revenue rose 9.54% YoY to HK$2.61bn and operating profit jumped 29.88% to HK$891m, but net profit fell 11.01% to HK$662m and EPS slipped 16.56% to HK$0.256, showing revenue growth without profit growth. At HK$15.40, the shares remain below the 60-day MA of HK$15.75, 56.52% below the 52-week high of HK$35.42 and down 37.35% YTD, though 18.01% above the 52-week low of HK$13.05 and above the 20-day MA of HK$14.26. Still, proposed US restrictions on Chinese biotech investment continue to weigh on sector sentiment.
- Nov, 4
3SBio staged a low-open, high-close session, finishing up 5.9% at HK$14.75 on 26.88 million shares worth HK$385.9 million, as renewed appetite for innovative-drug names and UBS's reiterated Buy rating carried the stock from a 13.92 morning trough to 14.78 at 15:10. The move sits against mixed fundamentals: Q2 2026 revenue rose 9.54% year on year to HK$2.61 billion and operating income jumped 29.88% to HK$891 million, yet net profit fell 11.01% to HK$662 million and EPS slipped 16.56% to HK$0.256. Price is above the 14.28 MA20 but below the 15.79 MA60, down 39.99% year to date, 58.36% below the 35.42 52-week high and just 13.03% above the 13.05 low of 26 October, with a 3.89x PE. Proposed US curbs on biotech investment in China remain unresolved, though.
- Oct, 27
News that the US plans to curb investment in Chinese biotech weighed on the sector, sending 3SBio 4.8% lower to HK$13.24 after opening at HK$13.91 and sliding through the session; turnover reached 24.77 million shares worth about HK$330 million, with the intraday low of HK$13.05 near the 52-week low set the previous day. Fundamentals cut against the price action: Q2 revenue rose 9.54% yoy to HK$2.61 billion and operating income climbed 29.88% to HK$891 million, yet net profit fell 11.01% to HK$662 million and EPS slipped 16.56% to HK$0.256, with PE around 3.49x and PB around 1.05x. The stock is down 46.14% year-to-date, 62.62% below its 52-week high of HK$35.42, and trades under its MA20 of HK$14.887. One analyst initiated coverage with a HK$17.8 target price, and the company repurchased 337,500 shares on 14 October; though peers weakened in tandem, suggesting sector-wide rather than company-specific pressure.
- Oct, 22
Dragged by a broadly weaker Hong Kong biotech sector, 3SBio opened at HK$14.33 on 22 October and slid through the session to close down 4.41% at HK$13.66, with the HK$13.46 touched at 13:52 BJ marking a fresh 52-week low on about HK$347 million turnover and a 1.01% turnover rate. The stock trades below its MA20 of HK$15.29 and MA60 of HK$16.30, down 44.43% year to date and 61.43% below its November 2025 high of HK$35.42. Fundamentals read differently from the tape: Q2 2026 revenue rose 9.54% year on year to HK$2.61 billion and operating income climbed 29.88% to HK$891 million, yet net profit fell 11.01% to HK$662 million. The company repurchased roughly 2.14 million shares across 12 to 14 October, and one brokerage initiated coverage with a HK$17.8 target price. At PE 3.61x and PB 1.08x, though, net profit has now declined for two consecutive quarters, with revenue growth yet to reach the bottom line.
News
Market Movers · 3SBIO drops 5% in Hong Kong trading
Weekly Review · Weekly Recap | 3SBIO -4.75%, consensus target above spot
Tip Ranks · Citic Securities Sticks to Its Buy Rating for 3SBio (TRSBF)
PUBT · SanRex proposes to acquire Frontage Holdings for HKD 2.370 per share
Weekly Review · Weekly Recap | 3SBIO +10.96%, consensus target above spot
Market Movers · 3SBio climbs 5%
Posts
View more- H
Hot trades in Hong Kong stocks (7.29)|Xiaomi's stock price hits a 1-month low, while innovative drug concepts buck the trend and rise!
The three major Hong Kong stock indices collectively retreated. WuXi AppTec's performance ignited the CRO sector, while tech stocks faced pressure, dragging down the indices.
- H
Hot Trades in Hong Kong Stocks (7.28)|Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday
Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's "Stablecoin Ordinance" will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.
